Gwilt P R, Tracewell W G
Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, USA.
Clin Pharmacokinet. 1998 May;34(5):347-58. doi: 10.2165/00003088-199834050-00002.
Hydroxyurea is used in the treatment of various forms of cancer, sickle-cell anaemia and HIV infection. Oral absorption of the drug is virtually complete, the volume of distribution is equivalent to total body water and elimination is through both renal and nonrenal mechanisms. Nonrenal elimination of hydroxyurea is characterised by Michaelis-Menten kinetics. Further studies are necessary to clarify several aspects of the pharmacokinetics and pharmacodynamics of hydroxyurea: the effect of age and disease state, concentration-effect relationship, the role of therapeutic drug monitoring, and the mechanisms of renal and nonrenal elimination. The recent development of improved assays for hydroxyurea should have benefits for future pharmacokinetic studies.
羟基脲用于治疗多种癌症、镰状细胞贫血和HIV感染。该药物口服吸收几乎完全,分布容积相当于总体液,通过肾脏和非肾脏机制消除。羟基脲的非肾脏消除具有米氏动力学特征。有必要进行进一步研究以阐明羟基脲药代动力学和药效学的几个方面:年龄和疾病状态的影响、浓度-效应关系、治疗药物监测的作用以及肾脏和非肾脏消除的机制。羟基脲改进检测方法的最新进展应为未来的药代动力学研究带来益处。